Psoriatic Disease in the US Latino Population: A Comprehensive Review

Overview

Journal Am J Clin Dermatol

Specialty Dermatology

Date 2019 Dec 18

PMID 31845122

Citations 4

Authors

Alyssa Gwen Ashbaugh

Chloe Ekelem

Yessica Landaverde

Natasha Atanaskova Mesinkovska

Affiliations

Soon will be listed here.

Abstract

Current evidence suggests that there are notable differences in the severity of psoriasis between racial and ethnic groups. While the US Latino population is growing rapidly, there is little research on the various factors impacting disease severity in this minority population. This review evaluates the current evidence on psoriasis in Latinos within the US. Psoriasis affects the US Latino population at a lower prevalence, with more severe disease and a greater quality-of-life impact than their White counterparts. In addition, Latinos with psoriasis experience higher rates of comorbidities, such as depression, obesity, and diabetes compared with Whites. There is evidence showing non-inferior or better response to systemic treatments, such as etanercept, secukinumab, and brodalumab, in this population. The combination of barriers to care and lack of involvement in research limit the current understanding of the mechanisms responsible for the pathologic outcomes and the environmental and social disparities observed. Future studies that reflect the growing proportion of minorities in the US may help close these knowledge gaps and improve care.

Citing Articles

High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Shams K, Montgomery J, Morley J, Gerasimaviciute V, Seesaghur A, Neasham D Dermatol Ther (Heidelb). 2025; .

PMID: 40080321 DOI: 10.1007/s13555-025-01358-6.

Differential access to psoriasis biologic information in English and Spanish.

Oscherwitz M, Lovell K, Markham D, Pichardo R, Feldman S JAAD Int. 2024; 15:87-90.

PMID: 38495539 PMC: 10940758. DOI: 10.1016/j.jdin.2023.12.001.

Racial and Ethnic Disparities in Treatment Initiation Among Patients with Newly Diagnosed Psoriatic Arthritis: A Retrospective Medicaid Claims Database Study.

Patel A, Ferrante S, Lin I, Fu A, Campbell A, Tieng A Rheumatol Ther. 2023; 10(5):1241-1253.

PMID: 37453020 PMC: 10468443. DOI: 10.1007/s40744-023-00580-y.

Socioeconomic predictors of cost and length of stay for erythroderma: a cross-sectional analysis of the national inpatient sample.

Kim Y, Bhandarkar A, Adeleye O, Zhu A, Bydon M, Vidal N Arch Dermatol Res. 2022; 315(4):869-877.

PMID: 36367570 DOI: 10.1007/s00403-022-02463-8.

Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States.

Yadav G, Yeung J, Miller-Monthrope Y, Lakhani O, Drudge C, Craigie S Dermatol Ther (Heidelb). 2022; 12(11):2401-2413.

PMID: 36131193 PMC: 9588130. DOI: 10.1007/s13555-022-00811-0.

References

Rachakonda T, Schupp C, Armstrong A . Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70(3):512-6. DOI: 10.1016/j.jaad.2013.11.013. View

Menter A, Korman N, Elmets C, Feldman S, Gelfand J, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011; 65(1):137-74. DOI: 10.1016/j.jaad.2010.11.055. View

Kaufman B, F Alexis A . Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. Am J Clin Dermatol. 2017; 19(3):405-423. DOI: 10.1007/s40257-017-0332-7. View

Poon A, Gray K, Franco G, Cerruti D, Schreck M, Delgado E . Cultural competence: serving Latino patients. J Pediatr Orthop. 2003; 23(4):546-9. View

Mitrani V . Reducing Health Disparities for Hispanics Through the Development of Culturally Tailored Interventions. Hisp Health Care Int. 2010; 7(1):2-4. PMC: 2868274. DOI: 10.1891/1540-4153.7.1.2. View

Charrow A, Xia F, Joyce C, Mostaghimi A . Diversity in Dermatology Clinical Trials: A Systematic Review. JAMA Dermatol. 2017; 153(2):193-198. DOI: 10.1001/jamadermatol.2016.4129. View

Hernandez-Vasquez A, Molinari L, Larrea N, Ciapponi A . Psoriasis in Latin America and the Caribbean: a systematic review. J Eur Acad Dermatol Venereol. 2017; 31(12):1991-1998. DOI: 10.1111/jdv.14393. View

Helmick C, Lee-Han H, Hirsch S, Baird T, Bartlett C . Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014; 47(1):37-45. PMC: 4653077. DOI: 10.1016/j.amepre.2014.02.012. View

F Alexis A, Blackcloud P . Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014; 7(11):16-24. PMC: 4255694. View

10.

Ford M, Siminoff L, Pickelsimer E, Mainous A, Smith D, Diaz V . Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work. 2013; 38(1):29-38. PMC: 3943359. DOI: 10.1093/hsw/hlt001. View

11.

Kurd S, Gelfand J . The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2008; 60(2):218-24. PMC: 4762027. DOI: 10.1016/j.jaad.2008.09.022. View

12.

Adsit S, Zaldivar E, Sofen H, Dei-Cas I, Maldonado-Garcia C, Penaranda E . Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials. Adv Ther. 2017; 34(6):1327-1339. PMC: 5487875. DOI: 10.1007/s12325-017-0521-z. View

13.

Shah S, Arthur A, Yang Y, Stevens S, F Alexis A . A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol. 2011; 10(8):866-72. View

14.

Robinson J, Penedo F, Hay J, Jablonski N . Recognizing Latinos' range of skin pigment and phototypes to enhance skin cancer prevention. Pigment Cell Melanoma Res. 2017; 30(5):488-492. PMC: 5568937. DOI: 10.1111/pcmr.12598. View

15.

Khalil F, Keehn C, Saeed S, Morgan M . Verrucous psoriasis: a distinctive clinicopathologic variant of psoriasis. Am J Dermatopathol. 2005; 27(3):204-7. DOI: 10.1097/01.dad.0000157450.39033.31. View

16.

Chandran V, Raychaudhuri S . Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2009; 34(3):J314-21. DOI: 10.1016/j.jaut.2009.12.001. View

17.

Raychaudhuri S, Gross J . Psoriasis risk factors: role of lifestyle practices. Cutis. 2000; 66(5):348-52. View

18.

Zink A, Herrmann M, Fischer T, Lauffer F, Garzorz-Stark N, Bohner A . Addiction: an underestimated problem in psoriasis health care. J Eur Acad Dermatol Venereol. 2017; 31(8):1308-1315. DOI: 10.1111/jdv.14204. View

19.

Chartier K, Caetano R . Ethnicity and health disparities in alcohol research. Alcohol Res Health. 2011; 33(1-2):152-60. PMC: 3887493. View

20.

Yan D, Afifi L, Jeon C, Cordoro K, Liao W . A cross-sectional study of psoriasis triggers among different ethno-racial groups. J Am Acad Dermatol. 2017; 77(4):756-758.e1. PMC: 5612377. DOI: 10.1016/j.jaad.2017.04.1109. View